Terbinafine-induced liver toxicity in the context of a SARS-CoV-2 pandemic: a case report

Authors

DOI:

https://doi.org/10.47892/rgp.2021.412.1280

Keywords:

Acute liver injury, drug-induced, Terbinafine, SARS-CoV-2

Abstract

Terbinafine is a drug that can induce acute liver damage. We present the case of a 40-year-old male patient who developed liver dysfunction after 35 days of terbinafine treatment for onychomycosis. The anatomopathological study showed: acute hepatitis in resolution, in addition to ductopenia and cholestasis. These findings, without a history of viral or autoimmune hepatitis, are consistent with the diagnosis of drug-induced liver damage (DILI). In this report we present the first case in our country of a patient who is affected by an acute liver disease: terbinafine-induced liver injury, to which SARS-CoV-2 infection was later associated in the context of a pandemic.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Published

06/30/2021

How to Cite

1.
Bustios Sanchez C, Sumire Umeres J, Asato Higa C, Monge Zapata V. Terbinafine-induced liver toxicity in the context of a SARS-CoV-2 pandemic: a case report. Rev Gastroenterol Peru [nternet]. 2021 Jun. 30 [cited 2024 May 18];41(2):107-11. vailable from: https://revistagastroperu.com/index.php/rgp/article/view/1280

Issue

Section

REPORTES DE CASOS